Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

Literature DB >> 29285500

Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

Denira Imamovic¹, Semir Vranic^1,2,3.

Abstract

Entities: Disease Gene

Year: 2017 PMID： 29285500 PMCID： PMC5733317 DOI： 10.21037/atm.2017.09.32

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

20 in total

1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors: Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal: Science Date: 2017-06-08 Impact factor: 47.728

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors: Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal: Nature Date: 2014-11-27 Impact factor: 49.962

3. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Authors: Ludmila Danilova; Hao Wang; Joel Sunshine; Genevieve J Kaunitz; Tricia R Cottrell; Haiying Xu; Jessica Esandrio; Robert A Anders; Leslie Cope; Drew M Pardoll; Charles G Drake; Janis M Taube
Journal: Proc Natl Acad Sci U S A Date: 2016-11-11 Impact factor: 11.205

Review 4. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Authors: Sandip Pravin Patel; Razelle Kurzrock
Journal: Mol Cancer Ther Date: 2015-02-18 Impact factor: 6.261

Review 5. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Authors: Tomas Jelinek; Jana Mihalyova; Michal Kascak; Juraj Duras; Roman Hajek
Journal: Immunology Date: 2017-08-04 Impact factor: 7.397

Review 6. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Authors: Vassiliki A Boussiotis
Journal: N Engl J Med Date: 2016-11-03 Impact factor: 91.245

Review 7. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.

Authors: David A Braun; Kelly P Burke; Eliezer M Van Allen
Journal: Clin Cancer Res Date: 2016-10-03 Impact factor: 12.531

8. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Authors: Marian L Burr; Christina E Sparbier; Yih-Chih Chan; James C Williamson; Katherine Woods; Paul A Beavis; Enid Y N Lam; Melissa A Henderson; Charles C Bell; Sabine Stolzenburg; Omer Gilan; Stuart Bloor; Tahereh Noori; David W Morgens; Michael C Bassik; Paul J Neeson; Andreas Behren; Phillip K Darcy; Sarah-Jane Dawson; Ilia Voskoboinik; Joseph A Trapani; Jonathan Cebon; Paul J Lehner; Mark A Dawson
Journal: Nature Date: 2017-08-16 Impact factor: 49.962

Review 9. Checkpoint inhibitors in hematological malignancies.

Authors: Chi Young Ok; Ken H Young
Journal: J Hematol Oncol Date: 2017-05-08 Impact factor: 17.388

10. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Authors: Riccardo Mezzadra; Chong Sun; Lucas T Jae; Raquel Gomez-Eerland; Evert de Vries; Wei Wu; Meike E W Logtenberg; Maarten Slagter; Elisa A Rozeman; Ingrid Hofland; Annegien Broeks; Hugo M Horlings; Lodewyk F A Wessels; Christian U Blank; Yanling Xiao; Albert J R Heck; Jannie Borst; Thijn R Brummelkamp; Ton N M Schumacher
Journal: Nature Date: 2017-08-16 Impact factor: 49.962

5 in total

Novel regulators of PD-L1 expression in cancer: CMTM6 and CMTM4-a new avenue to enhance the therapeutic benefits of immune checkpoint inhibitors.

1. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

2. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

3. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.

Review 4. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.

Review 5. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.

Review 6. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Review 7. Genomic Approaches to Understanding Response and Resistance to Immunotherapy.

8. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.

Review 9. Checkpoint inhibitors in hematological malignancies.

10. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.

Review 1. CMTM family proteins 1-8: roles in cancer biological processes and potential clinical value.

2. Association Between Intra-Tumoral Immune Response and Programmed Death Ligand 1 (PD-L1) in Gastric Cancer.

3. CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway.

4. Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma.

Review 5. The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.